Sun Pharma Surges to 52-Week High on South Africa Drug Approval Sun Pharmaceutical Industries Ltd. (Sun Pharma) experienced a significant stock surge, reaching a 52-week high of Rs 1,962.70 on the National Stock Exchange (NSE) on Wednesday. The sharp rise followed the approval of its generic diabetes drug by South Africa’s health regulator, the South African Health Products Regulatory Authority (SAHPRA). The regulatory green light allows the company to manufacture and market the injectable medication for adults with Type 2 diabetes that cannot be managed through diet and exercise alone. The drug, sold as a pre-filled pen in two strengths, is designed for once-a-week use, marking a key milestone in Sun Pharma’s expansion into international markets. The approval is notable as it represents only the second country where Sun Pharma has secured such clearance, with India being the first. Company COO Aalok Shanghvi highlighted the significance of the regulatory nod, stating it underscores the company’s capability to develop complex generic medicines that meet stringent quality standards globally. He emphasized the goal of enhancing access to evidence-based treatments, particularly in regions where healthcare resources are limited. The drug’s approval aligns with South Africa’s growing diabetes prevalence, driven by urbanization and lifestyle changes. The company noted that expanding treatment access is critical in addressing the rising number of cases, which has placed increasing pressure on healthcare systems. Sun Pharma’s strategic focus on such markets reflects its broader efforts to diversify its portfolio and strengthen its global footprint.#south_africa #sun_pharmaceutical_industries_ltd #south_african_health_products_regulatory_authority #aalok_shanghvi #innovacare_lifesciences
Sun Pharmaceutical Industries Ltd. Secures South African Approval for Generic Semaglutide Injection Sun Pharmaceutical Industries Ltd. announced on Wednesday, July 15, 2026, that it has obtained regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) to produce and distribute a generic version of semaglutide injection. This approval enables the company to market the drug in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. The decision marks a significant milestone for the pharmaceutical company, which plans to introduce the product to the market in the near future. The generic semaglutide injection will be available in a pre-filled, multi-dose injectable pen format, offering two dosage strengths: 2 mg/1.5 mL and 4 mg/3 mL. This design allows for flexible, once-weekly dosing, simplifying the treatment regimen for patients. The product’s availability is expected to enhance access to effective diabetes management options in South Africa, where the prevalence of type 2 diabetes is rising due to factors such as urbanization and lifestyle changes. Sun Pharmaceutical Industries highlighted that South Africa is the second market, following India, where the company has secured approval for the generic semaglutide. This achievement underscores the company’s capability to develop complex generic medicines that meet rigorous quality standards across diverse regulatory environments. Aalok Shanghvi, the company’s Chief Operating Officer, emphasized the importance of expanding access to affordable, evidence-based treatments.#sun_pharmaceutical_industries_ltd #south_african_health_products_regulatory_authority #aalok_shanghvi #type_2_diabetes_mellitus #semaglutide_injection
